Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.34 |
| ▸ | AHCY | P23526 | 1/20 | 0.34 |
| ▸ | TNK2 | Q07912 | 14/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.33 |
| ▸ | IGF1R | P08069 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21138157 | 0.88 | ADORA3 (0.50) | ADORA3AHCYTNK2 | |
| SCHEMBL21138193 | 0.86 | ADORA3 (0.44) | ADORA3FGFR2AHCYTNK2IGF1R | |
| SCHEMBL19917191 | 0.86 | ADORA3 (0.44) | ADORA3FGFR2AHCYTNK2IGF1R | |
| SCHEMBL21057310 | 0.86 | ADORA3 (0.47) | ADORA3FGFR2AHCYTNK2FGFR1 | |
| SCHEMBL21057510 | 0.86 | ADORA3 (0.44) | ADORA3FGFR2AHCYTNK2IGF1R | |
| SCHEMBL21138377 | 0.85 | HSD11B1 (0.36) | ADORA3 | |
| SCHEMBL21138747 | 0.83 | ADORA3 (0.53) | ADORA3FGFR2TNK2FGFR1IGF1R | |
| SCHEMBL21138169 | 0.83 | ADORA3 (0.53) | ADORA3FGFR2AHCYTNK2IGF1R | |
| SCHEMBL21159596 | 0.82 | ADORA3 (0.44) | ADORA3FGFR2AHCYTNK2IGF1R | |
| SCHEMBL21057503 | 0.82 | ADORA3 (0.52) | ADORA3FGFR2TNK2IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3505171-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2019-07-03 | — | — | EP | claimed |
| US-20190185479-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-06-20 | — | — | US | claimed |
| US-20260060970-A1 | Use of a Therapeutic Agent with Phosphodiesterase-7 Inhibitory Activity for the Treatment and Prevention of Diseases Associated with Chronic Fatigue, Exhaustion and/or Exertional Intolerance | MITODICURE GMBH (DE) | 2026-03-05 | — | — | US | disclosed |
| EP-3505171-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2019-07-03 | — | — | EP | disclosed |
| EP-3505171-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2019-07-03 | — | — | EP | disclosed |
| US-20190185479-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-06-20 | — | — | US | disclosed |
| US-20190185479-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260060970-A1 | Use of a Therapeutic Agent with Phosphodiesterase-7 Inhibitory Activity for the Treatment and Prevention of Diseases Associated with Chronic Fatigue, Exhaustion and/or Exertional Intolerance | PDE5A, PDE4C, PDE12 | ADORA3 3356/4885FGFR2 4251/4885AHCY 1944/4885 |
| US-20190185479-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | PDE7B, PDE3A, PDE7A | ADORA3 1484/4885FGFR2 4051/4885AHCY 1959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.